nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—VEGFA—muscle cancer	0.444	1	CbGaD
Vandetanib—ABCC1—Dactinomycin—muscle cancer	0.053	0.189	CbGbCtD
Vandetanib—ABCG2—Dactinomycin—muscle cancer	0.0354	0.126	CbGbCtD
Vandetanib—ABCC1—Vincristine—muscle cancer	0.0326	0.116	CbGbCtD
Vandetanib—ABCC1—Etoposide—muscle cancer	0.0299	0.106	CbGbCtD
Vandetanib—ABCG2—Vincristine—muscle cancer	0.0218	0.0777	CbGbCtD
Vandetanib—ABCC1—Doxorubicin—muscle cancer	0.0204	0.0726	CbGbCtD
Vandetanib—ABCG2—Etoposide—muscle cancer	0.02	0.0712	CbGbCtD
Vandetanib—ABCC1—Methotrexate—muscle cancer	0.0197	0.0703	CbGbCtD
Vandetanib—ABCG2—Doxorubicin—muscle cancer	0.0136	0.0486	CbGbCtD
Vandetanib—ABCG2—Methotrexate—muscle cancer	0.0132	0.0471	CbGbCtD
Vandetanib—ALB—Methotrexate—muscle cancer	0.00911	0.0324	CbGbCtD
Vandetanib—CYP3A4—Vincristine—muscle cancer	0.00472	0.0168	CbGbCtD
Vandetanib—CYP3A4—Etoposide—muscle cancer	0.00432	0.0154	CbGbCtD
Vandetanib—CYP3A4—Doxorubicin—muscle cancer	0.00295	0.0105	CbGbCtD
Vandetanib—KDR—hindlimb—muscle cancer	0.00208	0.0238	CbGeAlD
Vandetanib—KDR—appendage—muscle cancer	0.00178	0.0204	CbGeAlD
Vandetanib—PTK6—renal system—muscle cancer	0.00114	0.0131	CbGeAlD
Vandetanib—FLT4—embryo—muscle cancer	0.000901	0.0103	CbGeAlD
Vandetanib—ERBB3—embryo—muscle cancer	0.000857	0.00982	CbGeAlD
Vandetanib—ERBB3—Podofilox—Etoposide—muscle cancer	0.00084	0.242	CbGdCrCtD
Vandetanib—PTK6—vagina—muscle cancer	0.000827	0.00946	CbGeAlD
Vandetanib—LTK—head—muscle cancer	0.000796	0.00912	CbGeAlD
Vandetanib—FGR—embryo—muscle cancer	0.000795	0.0091	CbGeAlD
Vandetanib—RET—embryo—muscle cancer	0.000795	0.0091	CbGeAlD
Vandetanib—LTK—testis—muscle cancer	0.000769	0.00881	CbGeAlD
Vandetanib—EPHA8—head—muscle cancer	0.000764	0.00874	CbGeAlD
Vandetanib—FYN—embryo—muscle cancer	0.000741	0.00849	CbGeAlD
Vandetanib—EPHA8—testis—muscle cancer	0.000738	0.00844	CbGeAlD
Vandetanib—TEK—embryo—muscle cancer	0.000724	0.00829	CbGeAlD
Vandetanib—PLK4—bone marrow—muscle cancer	0.000711	0.00813	CbGeAlD
Vandetanib—VEGFA—smooth muscle tissue—muscle cancer	0.000702	0.00804	CbGeAlD
Vandetanib—FMO1—renal system—muscle cancer	0.000673	0.0077	CbGeAlD
Vandetanib—STK35—cardiac atrium—muscle cancer	0.000659	0.00754	CbGeAlD
Vandetanib—ERBB3—renal system—muscle cancer	0.000649	0.00743	CbGeAlD
Vandetanib—PLK4—Teniposide—Etoposide—muscle cancer	0.000644	0.186	CbGdCrCtD
Vandetanib—SRC—embryo—muscle cancer	0.000644	0.00737	CbGeAlD
Vandetanib—EPHA5—vagina—muscle cancer	0.000639	0.00732	CbGeAlD
Vandetanib—EPHA6—head—muscle cancer	0.000637	0.00729	CbGeAlD
Vandetanib—AXL—smooth muscle tissue—muscle cancer	0.000623	0.00713	CbGeAlD
Vandetanib—EPHA6—testis—muscle cancer	0.000615	0.00704	CbGeAlD
Vandetanib—PLK4—testis—muscle cancer	0.000607	0.00695	CbGeAlD
Vandetanib—RIPK2—cardiac atrium—muscle cancer	0.000607	0.00695	CbGeAlD
Vandetanib—VEGFA—cardiac atrium—muscle cancer	0.000606	0.00693	CbGeAlD
Vandetanib—RET—renal system—muscle cancer	0.000602	0.00689	CbGeAlD
Vandetanib—KDR—embryo—muscle cancer	0.000592	0.00678	CbGeAlD
Vandetanib—TYRO3—head—muscle cancer	0.000591	0.00676	CbGeAlD
Vandetanib—EPHA5—head—muscle cancer	0.000591	0.00676	CbGeAlD
Vandetanib—LYN—head—muscle cancer	0.000588	0.00673	CbGeAlD
Vandetanib—FYN—smooth muscle tissue—muscle cancer	0.000583	0.00667	CbGeAlD
Vandetanib—BMPR1B—head—muscle cancer	0.000579	0.00662	CbGeAlD
Vandetanib—MAP3K19—head—muscle cancer	0.000579	0.00662	CbGeAlD
Vandetanib—ERBB3—Vinblastine—Vincristine—muscle cancer	0.000578	0.167	CbGdCrCtD
Vandetanib—STK35—tendon—muscle cancer	0.000574	0.00657	CbGeAlD
Vandetanib—TYRO3—testis—muscle cancer	0.000571	0.00653	CbGeAlD
Vandetanib—MAP4K5—smooth muscle tissue—muscle cancer	0.00057	0.00652	CbGeAlD
Vandetanib—TEK—smooth muscle tissue—muscle cancer	0.00057	0.00652	CbGeAlD
Vandetanib—FLT3—bone marrow—muscle cancer	0.000568	0.0065	CbGeAlD
Vandetanib—FYN—renal system—muscle cancer	0.000561	0.00642	CbGeAlD
Vandetanib—ABL2—tendon—muscle cancer	0.000559	0.0064	CbGeAlD
Vandetanib—BMPR1B—testis—muscle cancer	0.000559	0.0064	CbGeAlD
Vandetanib—MAP3K19—testis—muscle cancer	0.000559	0.0064	CbGeAlD
Vandetanib—TEK—renal system—muscle cancer	0.000548	0.00628	CbGeAlD
Vandetanib—MKNK1—cardiac atrium—muscle cancer	0.000546	0.00625	CbGeAlD
Vandetanib—AXL—cardiac atrium—muscle cancer	0.000537	0.00615	CbGeAlD
Vandetanib—STK35—vagina—muscle cancer	0.000533	0.0061	CbGeAlD
Vandetanib—RIPK2—tendon—muscle cancer	0.000529	0.00606	CbGeAlD
Vandetanib—VEGFA—tendon—muscle cancer	0.000528	0.00604	CbGeAlD
Vandetanib—YES1—smooth muscle tissue—muscle cancer	0.000526	0.00602	CbGeAlD
Vandetanib—FMO1—tendon—muscle cancer	0.000525	0.00601	CbGeAlD
Vandetanib—ABL2—vagina—muscle cancer	0.000519	0.00594	CbGeAlD
Vandetanib—IRAK4—tendon—muscle cancer	0.000517	0.00592	CbGeAlD
Vandetanib—SLK—cardiac atrium—muscle cancer	0.000517	0.00592	CbGeAlD
Vandetanib—FLT4—bone marrow—muscle cancer	0.000515	0.0059	CbGeAlD
Vandetanib—RIPK2—bone marrow—muscle cancer	0.000513	0.00587	CbGeAlD
Vandetanib—PDGFRB—embryo—muscle cancer	0.000512	0.00587	CbGeAlD
Vandetanib—VEGFA—bone marrow—muscle cancer	0.000511	0.00585	CbGeAlD
Vandetanib—YES1—renal system—muscle cancer	0.000506	0.0058	CbGeAlD
Vandetanib—SRC—smooth muscle tissue—muscle cancer	0.000506	0.00579	CbGeAlD
Vandetanib—FYN—cardiac atrium—muscle cancer	0.000502	0.00575	CbGeAlD
Vandetanib—STK10—renal system—muscle cancer	0.000502	0.00574	CbGeAlD
Vandetanib—IRAK4—bone marrow—muscle cancer	0.000501	0.00573	CbGeAlD
Vandetanib—STK35—head—muscle cancer	0.000492	0.00563	CbGeAlD
Vandetanib—RIPK2—vagina—muscle cancer	0.000491	0.00562	CbGeAlD
Vandetanib—MAP4K5—cardiac atrium—muscle cancer	0.000491	0.00562	CbGeAlD
Vandetanib—TEK—cardiac atrium—muscle cancer	0.000491	0.00562	CbGeAlD
Vandetanib—VEGFA—vagina—muscle cancer	0.00049	0.00561	CbGeAlD
Vandetanib—FMO1—vagina—muscle cancer	0.000487	0.00558	CbGeAlD
Vandetanib—SRC—renal system—muscle cancer	0.000487	0.00558	CbGeAlD
Vandetanib—FLT3—testis—muscle cancer	0.000485	0.00555	CbGeAlD
Vandetanib—IRAK4—vagina—muscle cancer	0.00048	0.00549	CbGeAlD
Vandetanib—STK35—testis—muscle cancer	0.000475	0.00544	CbGeAlD
Vandetanib—RET—tendon—muscle cancer	0.00047	0.00538	CbGeAlD
Vandetanib—FGR—tendon—muscle cancer	0.00047	0.00538	CbGeAlD
Vandetanib—EPHB6—cardiac atrium—muscle cancer	0.000469	0.00537	CbGeAlD
Vandetanib—AXL—tendon—muscle cancer	0.000468	0.00536	CbGeAlD
Vandetanib—KDR—smooth muscle tissue—muscle cancer	0.000466	0.00533	CbGeAlD
Vandetanib—ABL2—testis—muscle cancer	0.000463	0.0053	CbGeAlD
Vandetanib—MKNK1—bone marrow—muscle cancer	0.000461	0.00527	CbGeAlD
Vandetanib—ABL1—embryo—muscle cancer	0.000457	0.00523	CbGeAlD
Vandetanib—FLT4—head—muscle cancer	0.000456	0.00522	CbGeAlD
Vandetanib—FGR—bone marrow—muscle cancer	0.000455	0.00521	CbGeAlD
Vandetanib—LCK—bone marrow—muscle cancer	0.000455	0.00521	CbGeAlD
Vandetanib—RIPK2—head—muscle cancer	0.000454	0.00519	CbGeAlD
Vandetanib—YES1—cardiac atrium—muscle cancer	0.000453	0.00519	CbGeAlD
Vandetanib—EGFR—testis—muscle cancer	0.000452	0.00518	CbGeAlD
Vandetanib—SLK—tendon—muscle cancer	0.00045	0.00516	CbGeAlD
Vandetanib—FMO1—head—muscle cancer	0.00045	0.00515	CbGeAlD
Vandetanib—KDR—renal system—muscle cancer	0.000448	0.00513	CbGeAlD
Vandetanib—IRAK4—head—muscle cancer	0.000443	0.00507	CbGeAlD
Vandetanib—MKNK1—vagina—muscle cancer	0.000441	0.00505	CbGeAlD
Vandetanib—FLT4—testis—muscle cancer	0.000441	0.00504	CbGeAlD
Vandetanib—RIPK2—testis—muscle cancer	0.000438	0.00502	CbGeAlD
Vandetanib—FYN—tendon—muscle cancer	0.000438	0.00501	CbGeAlD
Vandetanib—VEGFA—testis—muscle cancer	0.000437	0.005	CbGeAlD
Vandetanib—SLK—bone marrow—muscle cancer	0.000436	0.005	CbGeAlD
Vandetanib—SRC—cardiac atrium—muscle cancer	0.000436	0.00499	CbGeAlD
Vandetanib—LCK—vagina—muscle cancer	0.000436	0.00499	CbGeAlD
Vandetanib—FGR—vagina—muscle cancer	0.000436	0.00499	CbGeAlD
Vandetanib—ERBB3—head—muscle cancer	0.000434	0.00497	CbGeAlD
Vandetanib—AXL—vagina—muscle cancer	0.000434	0.00497	CbGeAlD
Vandetanib—MAP4K5—tendon—muscle cancer	0.000428	0.0049	CbGeAlD
Vandetanib—TEK—tendon—muscle cancer	0.000428	0.0049	CbGeAlD
Vandetanib—IRAK4—testis—muscle cancer	0.000428	0.0049	CbGeAlD
Vandetanib—FYN—bone marrow—muscle cancer	0.000424	0.00486	CbGeAlD
Vandetanib—FMO3—vagina—muscle cancer	0.000421	0.00482	CbGeAlD
Vandetanib—ERBB3—testis—muscle cancer	0.000419	0.0048	CbGeAlD
Vandetanib—SLK—vagina—muscle cancer	0.000418	0.00479	CbGeAlD
Vandetanib—MAP4K5—bone marrow—muscle cancer	0.000415	0.00475	CbGeAlD
Vandetanib—EPHB6—tendon—muscle cancer	0.000409	0.00468	CbGeAlD
Vandetanib—MKNK1—head—muscle cancer	0.000408	0.00467	CbGeAlD
Vandetanib—FYN—vagina—muscle cancer	0.000406	0.00465	CbGeAlD
Vandetanib—PDGFRB—smooth muscle tissue—muscle cancer	0.000403	0.00461	CbGeAlD
Vandetanib—FGR—head—muscle cancer	0.000403	0.00461	CbGeAlD
Vandetanib—RET—head—muscle cancer	0.000403	0.00461	CbGeAlD
Vandetanib—KDR—cardiac atrium—muscle cancer	0.000401	0.00459	CbGeAlD
Vandetanib—MAP2K5—cardiac atrium—muscle cancer	0.000401	0.00459	CbGeAlD
Vandetanib—AXL—head—muscle cancer	0.000401	0.00459	CbGeAlD
Vandetanib—MAP4K5—vagina—muscle cancer	0.000397	0.00455	CbGeAlD
Vandetanib—YES1—tendon—muscle cancer	0.000395	0.00453	CbGeAlD
Vandetanib—MKNK1—testis—muscle cancer	0.000394	0.00451	CbGeAlD
Vandetanib—STK10—tendon—muscle cancer	0.000392	0.00448	CbGeAlD
Vandetanib—LCK—testis—muscle cancer	0.000389	0.00445	CbGeAlD
Vandetanib—FGR—testis—muscle cancer	0.000389	0.00445	CbGeAlD
Vandetanib—RET—testis—muscle cancer	0.000389	0.00445	CbGeAlD
Vandetanib—FMO3—head—muscle cancer	0.000389	0.00445	CbGeAlD
Vandetanib—PDGFRB—renal system—muscle cancer	0.000388	0.00444	CbGeAlD
Vandetanib—AXL—testis—muscle cancer	0.000387	0.00444	CbGeAlD
Vandetanib—YES1—bone marrow—muscle cancer	0.000383	0.00438	CbGeAlD
Vandetanib—EPHB6—vagina—muscle cancer	0.00038	0.00435	CbGeAlD
Vandetanib—STK10—bone marrow—muscle cancer	0.000379	0.00434	CbGeAlD
Vandetanib—FMO3—testis—muscle cancer	0.000376	0.0043	CbGeAlD
Vandetanib—FYN—head—muscle cancer	0.000375	0.0043	CbGeAlD
Vandetanib—SLK—testis—muscle cancer	0.000373	0.00427	CbGeAlD
Vandetanib—TEK—head—muscle cancer	0.000367	0.0042	CbGeAlD
Vandetanib—MAP4K5—head—muscle cancer	0.000367	0.0042	CbGeAlD
Vandetanib—YES1—vagina—muscle cancer	0.000367	0.0042	CbGeAlD
Vandetanib—STK10—vagina—muscle cancer	0.000363	0.00416	CbGeAlD
Vandetanib—FYN—testis—muscle cancer	0.000363	0.00415	CbGeAlD
Vandetanib—ABL1—smooth muscle tissue—muscle cancer	0.000359	0.00411	CbGeAlD
Vandetanib—TEK—testis—muscle cancer	0.000354	0.00406	CbGeAlD
Vandetanib—MAP4K5—testis—muscle cancer	0.000354	0.00406	CbGeAlD
Vandetanib—EPHB6—head—muscle cancer	0.000351	0.00401	CbGeAlD
Vandetanib—KDR—tendon—muscle cancer	0.00035	0.004	CbGeAlD
Vandetanib—MAP2K5—tendon—muscle cancer	0.00035	0.004	CbGeAlD
Vandetanib—PDGFRB—cardiac atrium—muscle cancer	0.000347	0.00398	CbGeAlD
Vandetanib—ABL1—renal system—muscle cancer	0.000346	0.00396	CbGeAlD
Vandetanib—KDR—bone marrow—muscle cancer	0.000339	0.00388	CbGeAlD
Vandetanib—YES1—head—muscle cancer	0.000339	0.00388	CbGeAlD
Vandetanib—EPHB6—testis—muscle cancer	0.000339	0.00388	CbGeAlD
Vandetanib—STK10—head—muscle cancer	0.000336	0.00384	CbGeAlD
Vandetanib—YES1—testis—muscle cancer	0.000327	0.00375	CbGeAlD
Vandetanib—SRC—head—muscle cancer	0.000326	0.00373	CbGeAlD
Vandetanib—MAP2K5—vagina—muscle cancer	0.000325	0.00372	CbGeAlD
Vandetanib—KDR—vagina—muscle cancer	0.000325	0.00372	CbGeAlD
Vandetanib—STK10—testis—muscle cancer	0.000324	0.00371	CbGeAlD
Vandetanib—SRC—testis—muscle cancer	0.000315	0.0036	CbGeAlD
Vandetanib—PLK4—Epirubicin—Doxorubicin—muscle cancer	0.000311	0.0896	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Doxorubicin—muscle cancer	0.000311	0.0896	CbGdCrCtD
Vandetanib—ABL1—cardiac atrium—muscle cancer	0.00031	0.00354	CbGeAlD
Vandetanib—PDGFRB—tendon—muscle cancer	0.000303	0.00347	CbGeAlD
Vandetanib—MAP2K5—head—muscle cancer	0.0003	0.00343	CbGeAlD
Vandetanib—KDR—head—muscle cancer	0.0003	0.00343	CbGeAlD
Vandetanib—PDGFRB—bone marrow—muscle cancer	0.000293	0.00336	CbGeAlD
Vandetanib—KDR—testis—muscle cancer	0.00029	0.00332	CbGeAlD
Vandetanib—MAP2K5—testis—muscle cancer	0.00029	0.00332	CbGeAlD
Vandetanib—PDGFRB—vagina—muscle cancer	0.000281	0.00322	CbGeAlD
Vandetanib—ORM1—bone marrow—muscle cancer	0.000275	0.00315	CbGeAlD
Vandetanib—ABL1—tendon—muscle cancer	0.00027	0.00309	CbGeAlD
Vandetanib—ABL1—bone marrow—muscle cancer	0.000261	0.00299	CbGeAlD
Vandetanib—ABL1—Idarubicin—Doxorubicin—muscle cancer	0.000261	0.0754	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Doxorubicin—muscle cancer	0.000261	0.0754	CbGdCrCtD
Vandetanib—ABL1—Epirubicin—Doxorubicin—muscle cancer	0.000261	0.0754	CbGdCrCtD
Vandetanib—PDGFRB—head—muscle cancer	0.00026	0.00297	CbGeAlD
Vandetanib—PDGFRB—testis—muscle cancer	0.000251	0.00287	CbGeAlD
Vandetanib—ABL1—vagina—muscle cancer	0.00025	0.00287	CbGeAlD
Vandetanib—ABCC1—cardiac atrium—muscle cancer	0.000236	0.0027	CbGeAlD
Vandetanib—ABL1—head—muscle cancer	0.000231	0.00265	CbGeAlD
Vandetanib—ABL1—testis—muscle cancer	0.000223	0.00256	CbGeAlD
Vandetanib—Mediastinal disorder—Vincristine—muscle cancer	0.000217	0.00331	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Etoposide—muscle cancer	0.000216	0.00329	CcSEcCtD
Vandetanib—Renal failure—Etoposide—muscle cancer	0.000214	0.00326	CcSEcCtD
Vandetanib—Blood bilirubin increased—Doxorubicin—muscle cancer	0.000213	0.00325	CcSEcCtD
Vandetanib—Alopecia—Vincristine—muscle cancer	0.000213	0.00325	CcSEcCtD
Vandetanib—Stomatitis—Etoposide—muscle cancer	0.000212	0.00323	CcSEcCtD
Vandetanib—Creatinine increased—Doxorubicin—muscle cancer	0.000212	0.00323	CcSEcCtD
Vandetanib—Mental disorder—Vincristine—muscle cancer	0.000211	0.00322	CcSEcCtD
Vandetanib—Bladder pain—Methotrexate—muscle cancer	0.000211	0.00321	CcSEcCtD
Vandetanib—Neoplasm—Methotrexate—muscle cancer	0.000211	0.00321	CcSEcCtD
Vandetanib—ALB—testis—muscle cancer	0.000206	0.00236	CbGeAlD
Vandetanib—Hepatobiliary disease—Etoposide—muscle cancer	0.000206	0.00313	CcSEcCtD
Vandetanib—ABCC1—tendon—muscle cancer	0.000206	0.00235	CbGeAlD
Vandetanib—Sepsis—Methotrexate—muscle cancer	0.000202	0.00308	CcSEcCtD
Vandetanib—Cystitis noninfective—Doxorubicin—muscle cancer	0.000197	0.003	CcSEcCtD
Vandetanib—Cystitis—Doxorubicin—muscle cancer	0.000195	0.00297	CcSEcCtD
Vandetanib—Colitis—Doxorubicin—muscle cancer	0.000194	0.00295	CcSEcCtD
Vandetanib—Urinary tract disorder—Etoposide—muscle cancer	0.000193	0.00294	CcSEcCtD
Vandetanib—Oedema—Dactinomycin—muscle cancer	0.000192	0.00292	CcSEcCtD
Vandetanib—Urethral disorder—Etoposide—muscle cancer	0.000192	0.00292	CcSEcCtD
Vandetanib—ABCC1—vagina—muscle cancer	0.000191	0.00218	CbGeAlD
Vandetanib—Infection—Dactinomycin—muscle cancer	0.000191	0.0029	CcSEcCtD
Vandetanib—Thrombocytopenia—Dactinomycin—muscle cancer	0.000188	0.00286	CcSEcCtD
Vandetanib—Dry eye—Doxorubicin—muscle cancer	0.000186	0.00284	CcSEcCtD
Vandetanib—Erythema multiforme—Etoposide—muscle cancer	0.000185	0.00281	CcSEcCtD
Vandetanib—Eye disorder—Etoposide—muscle cancer	0.000183	0.00278	CcSEcCtD
Vandetanib—Bladder pain—Doxorubicin—muscle cancer	0.000183	0.00278	CcSEcCtD
Vandetanib—Neoplasm—Doxorubicin—muscle cancer	0.000183	0.00278	CcSEcCtD
Vandetanib—Convulsion—Vincristine—muscle cancer	0.000182	0.00277	CcSEcCtD
Vandetanib—Cardiac disorder—Etoposide—muscle cancer	0.000181	0.00276	CcSEcCtD
Vandetanib—Hypertension—Vincristine—muscle cancer	0.000181	0.00276	CcSEcCtD
Vandetanib—Angiopathy—Etoposide—muscle cancer	0.000177	0.0027	CcSEcCtD
Vandetanib—Mediastinal disorder—Etoposide—muscle cancer	0.000176	0.00268	CcSEcCtD
Vandetanib—Sepsis—Doxorubicin—muscle cancer	0.000175	0.00267	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000175	0.00266	CcSEcCtD
Vandetanib—Alopecia—Etoposide—muscle cancer	0.000173	0.00263	CcSEcCtD
Vandetanib—Lethargy—Methotrexate—muscle cancer	0.000173	0.00263	CcSEcCtD
Vandetanib—Oedema—Vincristine—muscle cancer	0.000171	0.00261	CcSEcCtD
Vandetanib—Infection—Vincristine—muscle cancer	0.00017	0.00259	CcSEcCtD
Vandetanib—ABCC1—testis—muscle cancer	0.00017	0.00195	CbGeAlD
Vandetanib—Nervous system disorder—Vincristine—muscle cancer	0.000168	0.00256	CcSEcCtD
Vandetanib—Thrombocytopenia—Vincristine—muscle cancer	0.000168	0.00255	CcSEcCtD
Vandetanib—Decreased appetite—Dactinomycin—muscle cancer	0.000167	0.00254	CcSEcCtD
Vandetanib—Dysgeusia—Etoposide—muscle cancer	0.000167	0.00254	CcSEcCtD
Vandetanib—Fatigue—Dactinomycin—muscle cancer	0.000165	0.00252	CcSEcCtD
Vandetanib—ABCG2—bone marrow—muscle cancer	0.000165	0.00189	CbGeAlD
Vandetanib—Pain—Dactinomycin—muscle cancer	0.000164	0.0025	CcSEcCtD
Vandetanib—Muscle spasms—Etoposide—muscle cancer	0.000164	0.00249	CcSEcCtD
Vandetanib—ABCG2—vagina—muscle cancer	0.000158	0.00181	CbGeAlD
Vandetanib—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000157	0.00239	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000156	0.00238	CcSEcCtD
Vandetanib—Insomnia—Vincristine—muscle cancer	0.000155	0.00236	CcSEcCtD
Vandetanib—Paraesthesia—Vincristine—muscle cancer	0.000154	0.00234	CcSEcCtD
Vandetanib—Dermatitis bullous—Doxorubicin—muscle cancer	0.000153	0.00233	CcSEcCtD
Vandetanib—CYP3A4—renal system—muscle cancer	0.000152	0.00174	CbGeAlD
Vandetanib—Body temperature increased—Dactinomycin—muscle cancer	0.000152	0.00231	CcSEcCtD
Vandetanib—Abdominal pain—Dactinomycin—muscle cancer	0.000152	0.00231	CcSEcCtD
Vandetanib—Cardiac failure—Doxorubicin—muscle cancer	0.00015	0.00229	CcSEcCtD
Vandetanib—Hypoglycaemia—Doxorubicin—muscle cancer	0.00015	0.00229	CcSEcCtD
Vandetanib—Loss of consciousness—Etoposide—muscle cancer	0.00015	0.00228	CcSEcCtD
Vandetanib—Lethargy—Doxorubicin—muscle cancer	0.00015	0.00228	CcSEcCtD
Vandetanib—Decreased appetite—Vincristine—muscle cancer	0.000149	0.00227	CcSEcCtD
Vandetanib—Cough—Etoposide—muscle cancer	0.000149	0.00226	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Vincristine—muscle cancer	0.000148	0.00225	CcSEcCtD
Vandetanib—Fatigue—Vincristine—muscle cancer	0.000148	0.00225	CcSEcCtD
Vandetanib—Convulsion—Etoposide—muscle cancer	0.000147	0.00224	CcSEcCtD
Vandetanib—Hyponatraemia—Doxorubicin—muscle cancer	0.000147	0.00224	CcSEcCtD
Vandetanib—Hypertension—Etoposide—muscle cancer	0.000147	0.00224	CcSEcCtD
Vandetanib—Constipation—Vincristine—muscle cancer	0.000147	0.00223	CcSEcCtD
Vandetanib—Pain—Vincristine—muscle cancer	0.000147	0.00223	CcSEcCtD
Vandetanib—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	0.000147	0.00223	CcSEcCtD
Vandetanib—Chest pain—Etoposide—muscle cancer	0.000145	0.00221	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000144	0.00219	CcSEcCtD
Vandetanib—Pancreatitis—Methotrexate—muscle cancer	0.000143	0.00218	CcSEcCtD
Vandetanib—ABCG2—testis—muscle cancer	0.000141	0.00161	CbGeAlD
Vandetanib—Gastrointestinal pain—Vincristine—muscle cancer	0.00014	0.00213	CcSEcCtD
Vandetanib—Cardiac arrest—Doxorubicin—muscle cancer	0.000139	0.00212	CcSEcCtD
Vandetanib—Infection—Etoposide—muscle cancer	0.000138	0.0021	CcSEcCtD
Vandetanib—Asthenia—Dactinomycin—muscle cancer	0.000138	0.0021	CcSEcCtD
Vandetanib—Blood creatinine increased—Doxorubicin—muscle cancer	0.000137	0.00209	CcSEcCtD
Vandetanib—Dysuria—Methotrexate—muscle cancer	0.000137	0.00208	CcSEcCtD
Vandetanib—Neutropenia—Methotrexate—muscle cancer	0.000137	0.00208	CcSEcCtD
Vandetanib—Dehydration—Doxorubicin—muscle cancer	0.000136	0.00207	CcSEcCtD
Vandetanib—Thrombocytopenia—Etoposide—muscle cancer	0.000136	0.00207	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000136	0.00207	CcSEcCtD
Vandetanib—Abdominal pain—Vincristine—muscle cancer	0.000136	0.00206	CcSEcCtD
Vandetanib—Body temperature increased—Vincristine—muscle cancer	0.000136	0.00206	CcSEcCtD
Vandetanib—Skin disorder—Etoposide—muscle cancer	0.000135	0.00205	CcSEcCtD
Vandetanib—Dry skin—Doxorubicin—muscle cancer	0.000134	0.00204	CcSEcCtD
Vandetanib—Photosensitivity reaction—Methotrexate—muscle cancer	0.000134	0.00203	CcSEcCtD
Vandetanib—Hypokalaemia—Doxorubicin—muscle cancer	0.000133	0.00203	CcSEcCtD
Vandetanib—Diarrhoea—Dactinomycin—muscle cancer	0.000131	0.002	CcSEcCtD
Vandetanib—Pneumonia—Methotrexate—muscle cancer	0.000131	0.002	CcSEcCtD
Vandetanib—Nasopharyngitis—Doxorubicin—muscle cancer	0.000131	0.00199	CcSEcCtD
Vandetanib—Infestation NOS—Methotrexate—muscle cancer	0.00013	0.00199	CcSEcCtD
Vandetanib—Infestation—Methotrexate—muscle cancer	0.00013	0.00199	CcSEcCtD
Vandetanib—Depression—Methotrexate—muscle cancer	0.00013	0.00198	CcSEcCtD
Vandetanib—Gastritis—Doxorubicin—muscle cancer	0.00013	0.00197	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000129	0.00197	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000129	0.00197	CcSEcCtD
Vandetanib—Renal failure—Methotrexate—muscle cancer	0.000128	0.00195	CcSEcCtD
Vandetanib—Stomatitis—Methotrexate—muscle cancer	0.000127	0.00194	CcSEcCtD
Vandetanib—Conjunctivitis—Methotrexate—muscle cancer	0.000127	0.00193	CcSEcCtD
Vandetanib—Dysphagia—Doxorubicin—muscle cancer	0.000127	0.00193	CcSEcCtD
Vandetanib—Influenza—Doxorubicin—muscle cancer	0.000127	0.00193	CcSEcCtD
Vandetanib—Paraesthesia—Etoposide—muscle cancer	0.000125	0.0019	CcSEcCtD
Vandetanib—Haematuria—Methotrexate—muscle cancer	0.000124	0.00189	CcSEcCtD
Vandetanib—Pancreatitis—Doxorubicin—muscle cancer	0.000124	0.00189	CcSEcCtD
Vandetanib—Dyspnoea—Etoposide—muscle cancer	0.000124	0.00188	CcSEcCtD
Vandetanib—Hepatobiliary disease—Methotrexate—muscle cancer	0.000123	0.00188	CcSEcCtD
Vandetanib—Epistaxis—Methotrexate—muscle cancer	0.000123	0.00187	CcSEcCtD
Vandetanib—Asthenia—Vincristine—muscle cancer	0.000123	0.00187	CcSEcCtD
Vandetanib—Vomiting—Dactinomycin—muscle cancer	0.000122	0.00186	CcSEcCtD
Vandetanib—Bronchitis—Doxorubicin—muscle cancer	0.000122	0.00185	CcSEcCtD
Vandetanib—Rash—Dactinomycin—muscle cancer	0.000121	0.00184	CcSEcCtD
Vandetanib—Decreased appetite—Etoposide—muscle cancer	0.000121	0.00184	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Etoposide—muscle cancer	0.00012	0.00182	CcSEcCtD
Vandetanib—Fatigue—Etoposide—muscle cancer	0.00012	0.00182	CcSEcCtD
Vandetanib—Pain—Etoposide—muscle cancer	0.000119	0.00181	CcSEcCtD
Vandetanib—Constipation—Etoposide—muscle cancer	0.000119	0.00181	CcSEcCtD
Vandetanib—Dysuria—Doxorubicin—muscle cancer	0.000118	0.0018	CcSEcCtD
Vandetanib—Neutropenia—Doxorubicin—muscle cancer	0.000118	0.0018	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000118	0.00179	CcSEcCtD
Vandetanib—Haemoglobin—Methotrexate—muscle cancer	0.000118	0.00179	CcSEcCtD
Vandetanib—Diarrhoea—Vincristine—muscle cancer	0.000117	0.00179	CcSEcCtD
Vandetanib—Haemorrhage—Methotrexate—muscle cancer	0.000117	0.00178	CcSEcCtD
Vandetanib—Pollakiuria—Doxorubicin—muscle cancer	0.000117	0.00178	CcSEcCtD
Vandetanib—Urinary tract disorder—Methotrexate—muscle cancer	0.000116	0.00176	CcSEcCtD
Vandetanib—Photosensitivity reaction—Doxorubicin—muscle cancer	0.000116	0.00176	CcSEcCtD
Vandetanib—Urethral disorder—Methotrexate—muscle cancer	0.000115	0.00175	CcSEcCtD
Vandetanib—Weight decreased—Doxorubicin—muscle cancer	0.000115	0.00174	CcSEcCtD
Vandetanib—Hyperglycaemia—Doxorubicin—muscle cancer	0.000114	0.00174	CcSEcCtD
Vandetanib—Nausea—Dactinomycin—muscle cancer	0.000114	0.00173	CcSEcCtD
Vandetanib—Pneumonia—Doxorubicin—muscle cancer	0.000114	0.00173	CcSEcCtD
Vandetanib—Gastrointestinal pain—Etoposide—muscle cancer	0.000114	0.00173	CcSEcCtD
Vandetanib—Dizziness—Vincristine—muscle cancer	0.000113	0.00173	CcSEcCtD
Vandetanib—Infestation NOS—Doxorubicin—muscle cancer	0.000113	0.00172	CcSEcCtD
Vandetanib—Infestation—Doxorubicin—muscle cancer	0.000113	0.00172	CcSEcCtD
Vandetanib—Visual impairment—Methotrexate—muscle cancer	0.000113	0.00172	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000112	0.0017	CcSEcCtD
Vandetanib—Renal failure—Doxorubicin—muscle cancer	0.000111	0.00169	CcSEcCtD
Vandetanib—Erythema multiforme—Methotrexate—muscle cancer	0.000111	0.00169	CcSEcCtD
Vandetanib—Stomatitis—Doxorubicin—muscle cancer	0.00011	0.00168	CcSEcCtD
Vandetanib—Body temperature increased—Etoposide—muscle cancer	0.00011	0.00167	CcSEcCtD
Vandetanib—Abdominal pain—Etoposide—muscle cancer	0.00011	0.00167	CcSEcCtD
Vandetanib—Conjunctivitis—Doxorubicin—muscle cancer	0.00011	0.00167	CcSEcCtD
Vandetanib—Urinary tract infection—Doxorubicin—muscle cancer	0.00011	0.00167	CcSEcCtD
Vandetanib—Eye disorder—Methotrexate—muscle cancer	0.000109	0.00167	CcSEcCtD
Vandetanib—Vomiting—Vincristine—muscle cancer	0.000109	0.00166	CcSEcCtD
Vandetanib—Cardiac disorder—Methotrexate—muscle cancer	0.000109	0.00165	CcSEcCtD
Vandetanib—Rash—Vincristine—muscle cancer	0.000108	0.00165	CcSEcCtD
Vandetanib—Dermatitis—Vincristine—muscle cancer	0.000108	0.00164	CcSEcCtD
Vandetanib—Haematuria—Doxorubicin—muscle cancer	0.000108	0.00164	CcSEcCtD
Vandetanib—Headache—Vincristine—muscle cancer	0.000107	0.00163	CcSEcCtD
Vandetanib—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000107	0.00163	CcSEcCtD
Vandetanib—Epistaxis—Doxorubicin—muscle cancer	0.000107	0.00162	CcSEcCtD
Vandetanib—Angiopathy—Methotrexate—muscle cancer	0.000106	0.00162	CcSEcCtD
Vandetanib—Sinusitis—Doxorubicin—muscle cancer	0.000106	0.00161	CcSEcCtD
Vandetanib—Mediastinal disorder—Methotrexate—muscle cancer	0.000106	0.00161	CcSEcCtD
Vandetanib—Alopecia—Methotrexate—muscle cancer	0.000103	0.00157	CcSEcCtD
Vandetanib—Bradycardia—Doxorubicin—muscle cancer	0.000103	0.00157	CcSEcCtD
Vandetanib—Mental disorder—Methotrexate—muscle cancer	0.000103	0.00156	CcSEcCtD
Vandetanib—Malnutrition—Methotrexate—muscle cancer	0.000102	0.00155	CcSEcCtD
Vandetanib—Haemoglobin—Doxorubicin—muscle cancer	0.000102	0.00155	CcSEcCtD
Vandetanib—Nausea—Vincristine—muscle cancer	0.000102	0.00155	CcSEcCtD
Vandetanib—Haemorrhage—Doxorubicin—muscle cancer	0.000101	0.00154	CcSEcCtD
Vandetanib—Urinary tract disorder—Doxorubicin—muscle cancer	0.0001	0.00152	CcSEcCtD
Vandetanib—Dysgeusia—Methotrexate—muscle cancer	9.98e-05	0.00152	CcSEcCtD
Vandetanib—Asthenia—Etoposide—muscle cancer	9.96e-05	0.00152	CcSEcCtD
Vandetanib—Urethral disorder—Doxorubicin—muscle cancer	9.94e-05	0.00151	CcSEcCtD
Vandetanib—Pruritus—Etoposide—muscle cancer	9.83e-05	0.0015	CcSEcCtD
Vandetanib—Visual impairment—Doxorubicin—muscle cancer	9.77e-05	0.00149	CcSEcCtD
Vandetanib—Vision blurred—Methotrexate—muscle cancer	9.61e-05	0.00146	CcSEcCtD
Vandetanib—Erythema multiforme—Doxorubicin—muscle cancer	9.59e-05	0.00146	CcSEcCtD
Vandetanib—Diarrhoea—Etoposide—muscle cancer	9.5e-05	0.00145	CcSEcCtD
Vandetanib—Eye disorder—Doxorubicin—muscle cancer	9.48e-05	0.00144	CcSEcCtD
Vandetanib—Cardiac disorder—Doxorubicin—muscle cancer	9.41e-05	0.00143	CcSEcCtD
Vandetanib—Angiopathy—Doxorubicin—muscle cancer	9.2e-05	0.0014	CcSEcCtD
Vandetanib—Dizziness—Etoposide—muscle cancer	9.18e-05	0.0014	CcSEcCtD
Vandetanib—Mediastinal disorder—Doxorubicin—muscle cancer	9.14e-05	0.00139	CcSEcCtD
Vandetanib—Arrhythmia—Doxorubicin—muscle cancer	9.06e-05	0.00138	CcSEcCtD
Vandetanib—Alopecia—Doxorubicin—muscle cancer	8.96e-05	0.00136	CcSEcCtD
Vandetanib—Cough—Methotrexate—muscle cancer	8.89e-05	0.00135	CcSEcCtD
Vandetanib—Mental disorder—Doxorubicin—muscle cancer	8.88e-05	0.00135	CcSEcCtD
Vandetanib—Convulsion—Methotrexate—muscle cancer	8.83e-05	0.00134	CcSEcCtD
Vandetanib—Vomiting—Etoposide—muscle cancer	8.83e-05	0.00134	CcSEcCtD
Vandetanib—Malnutrition—Doxorubicin—muscle cancer	8.83e-05	0.00134	CcSEcCtD
Vandetanib—Rash—Etoposide—muscle cancer	8.76e-05	0.00133	CcSEcCtD
Vandetanib—Dermatitis—Etoposide—muscle cancer	8.75e-05	0.00133	CcSEcCtD
Vandetanib—Headache—Etoposide—muscle cancer	8.7e-05	0.00132	CcSEcCtD
Vandetanib—Arthralgia—Methotrexate—muscle cancer	8.68e-05	0.00132	CcSEcCtD
Vandetanib—Chest pain—Methotrexate—muscle cancer	8.68e-05	0.00132	CcSEcCtD
Vandetanib—Dysgeusia—Doxorubicin—muscle cancer	8.64e-05	0.00132	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	8.62e-05	0.00131	CcSEcCtD
Vandetanib—Muscle spasms—Doxorubicin—muscle cancer	8.49e-05	0.00129	CcSEcCtD
Vandetanib—Vision blurred—Doxorubicin—muscle cancer	8.32e-05	0.00127	CcSEcCtD
Vandetanib—Infection—Methotrexate—muscle cancer	8.26e-05	0.00126	CcSEcCtD
Vandetanib—Nausea—Etoposide—muscle cancer	8.25e-05	0.00126	CcSEcCtD
Vandetanib—Nervous system disorder—Methotrexate—muscle cancer	8.16e-05	0.00124	CcSEcCtD
Vandetanib—Thrombocytopenia—Methotrexate—muscle cancer	8.15e-05	0.00124	CcSEcCtD
Vandetanib—Skin disorder—Methotrexate—muscle cancer	8.08e-05	0.00123	CcSEcCtD
Vandetanib—Loss of consciousness—Doxorubicin—muscle cancer	7.76e-05	0.00118	CcSEcCtD
Vandetanib—Cough—Doxorubicin—muscle cancer	7.7e-05	0.00117	CcSEcCtD
Vandetanib—Convulsion—Doxorubicin—muscle cancer	7.65e-05	0.00116	CcSEcCtD
Vandetanib—Hypertension—Doxorubicin—muscle cancer	7.62e-05	0.00116	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Methotrexate—muscle cancer	7.58e-05	0.00115	CcSEcCtD
Vandetanib—Insomnia—Methotrexate—muscle cancer	7.52e-05	0.00115	CcSEcCtD
Vandetanib—Chest pain—Doxorubicin—muscle cancer	7.51e-05	0.00114	CcSEcCtD
Vandetanib—Arthralgia—Doxorubicin—muscle cancer	7.51e-05	0.00114	CcSEcCtD
Vandetanib—Anxiety—Doxorubicin—muscle cancer	7.49e-05	0.00114	CcSEcCtD
Vandetanib—Paraesthesia—Methotrexate—muscle cancer	7.47e-05	0.00114	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	7.46e-05	0.00114	CcSEcCtD
Vandetanib—Dyspnoea—Methotrexate—muscle cancer	7.42e-05	0.00113	CcSEcCtD
Vandetanib—Dry mouth—Doxorubicin—muscle cancer	7.35e-05	0.00112	CcSEcCtD
Vandetanib—Dyspepsia—Methotrexate—muscle cancer	7.32e-05	0.00111	CcSEcCtD
Vandetanib—Decreased appetite—Methotrexate—muscle cancer	7.23e-05	0.0011	CcSEcCtD
Vandetanib—Oedema—Doxorubicin—muscle cancer	7.2e-05	0.0011	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Methotrexate—muscle cancer	7.18e-05	0.00109	CcSEcCtD
Vandetanib—Fatigue—Methotrexate—muscle cancer	7.17e-05	0.00109	CcSEcCtD
Vandetanib—Infection—Doxorubicin—muscle cancer	7.16e-05	0.00109	CcSEcCtD
Vandetanib—Pain—Methotrexate—muscle cancer	7.11e-05	0.00108	CcSEcCtD
Vandetanib—Nervous system disorder—Doxorubicin—muscle cancer	7.06e-05	0.00108	CcSEcCtD
Vandetanib—Thrombocytopenia—Doxorubicin—muscle cancer	7.05e-05	0.00107	CcSEcCtD
Vandetanib—Skin disorder—Doxorubicin—muscle cancer	7e-05	0.00106	CcSEcCtD
Vandetanib—Gastrointestinal pain—Methotrexate—muscle cancer	6.8e-05	0.00104	CcSEcCtD
Vandetanib—Abdominal pain—Methotrexate—muscle cancer	6.58e-05	0.001	CcSEcCtD
Vandetanib—Body temperature increased—Methotrexate—muscle cancer	6.58e-05	0.001	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Doxorubicin—muscle cancer	6.56e-05	0.000999	CcSEcCtD
Vandetanib—Insomnia—Doxorubicin—muscle cancer	6.52e-05	0.000992	CcSEcCtD
Vandetanib—Paraesthesia—Doxorubicin—muscle cancer	6.47e-05	0.000984	CcSEcCtD
Vandetanib—Dyspnoea—Doxorubicin—muscle cancer	6.42e-05	0.000977	CcSEcCtD
Vandetanib—Dyspepsia—Doxorubicin—muscle cancer	6.34e-05	0.000965	CcSEcCtD
Vandetanib—Decreased appetite—Doxorubicin—muscle cancer	6.26e-05	0.000953	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Doxorubicin—muscle cancer	6.22e-05	0.000947	CcSEcCtD
Vandetanib—Fatigue—Doxorubicin—muscle cancer	6.21e-05	0.000945	CcSEcCtD
Vandetanib—Constipation—Doxorubicin—muscle cancer	6.16e-05	0.000938	CcSEcCtD
Vandetanib—Pain—Doxorubicin—muscle cancer	6.16e-05	0.000938	CcSEcCtD
Vandetanib—Asthenia—Methotrexate—muscle cancer	5.97e-05	0.000908	CcSEcCtD
Vandetanib—Gastrointestinal pain—Doxorubicin—muscle cancer	5.89e-05	0.000897	CcSEcCtD
Vandetanib—Pruritus—Methotrexate—muscle cancer	5.89e-05	0.000896	CcSEcCtD
Vandetanib—Abdominal pain—Doxorubicin—muscle cancer	5.69e-05	0.000867	CcSEcCtD
Vandetanib—Body temperature increased—Doxorubicin—muscle cancer	5.69e-05	0.000867	CcSEcCtD
Vandetanib—Diarrhoea—Methotrexate—muscle cancer	5.69e-05	0.000866	CcSEcCtD
Vandetanib—Dizziness—Methotrexate—muscle cancer	5.5e-05	0.000837	CcSEcCtD
Vandetanib—Vomiting—Methotrexate—muscle cancer	5.29e-05	0.000805	CcSEcCtD
Vandetanib—Rash—Methotrexate—muscle cancer	5.25e-05	0.000798	CcSEcCtD
Vandetanib—Dermatitis—Methotrexate—muscle cancer	5.24e-05	0.000798	CcSEcCtD
Vandetanib—Headache—Methotrexate—muscle cancer	5.21e-05	0.000793	CcSEcCtD
Vandetanib—Asthenia—Doxorubicin—muscle cancer	5.17e-05	0.000787	CcSEcCtD
Vandetanib—Pruritus—Doxorubicin—muscle cancer	5.1e-05	0.000776	CcSEcCtD
Vandetanib—Nausea—Methotrexate—muscle cancer	4.94e-05	0.000752	CcSEcCtD
Vandetanib—Diarrhoea—Doxorubicin—muscle cancer	4.93e-05	0.00075	CcSEcCtD
Vandetanib—Dizziness—Doxorubicin—muscle cancer	4.76e-05	0.000725	CcSEcCtD
Vandetanib—Vomiting—Doxorubicin—muscle cancer	4.58e-05	0.000697	CcSEcCtD
Vandetanib—Rash—Doxorubicin—muscle cancer	4.54e-05	0.000691	CcSEcCtD
Vandetanib—Dermatitis—Doxorubicin—muscle cancer	4.54e-05	0.000691	CcSEcCtD
Vandetanib—Headache—Doxorubicin—muscle cancer	4.51e-05	0.000687	CcSEcCtD
Vandetanib—Nausea—Doxorubicin—muscle cancer	4.28e-05	0.000651	CcSEcCtD
Vandetanib—ABCC1—Metabolism—MED12—muscle cancer	1.7e-05	0.000143	CbGpPWpGaD
Vandetanib—BLK—Immune System—KIT—muscle cancer	1.7e-05	0.000143	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—KIT—muscle cancer	1.7e-05	0.000143	CbGpPWpGaD
Vandetanib—FGR—Immune System—KIT—muscle cancer	1.7e-05	0.000143	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HMGA1—muscle cancer	1.69e-05	0.000142	CbGpPWpGaD
Vandetanib—LCK—Disease—ENO2—muscle cancer	1.69e-05	0.000142	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—KIT—muscle cancer	1.68e-05	0.000142	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—FOXO1—muscle cancer	1.67e-05	0.000141	CbGpPWpGaD
Vandetanib—LYN—Axon guidance—VEGFA—muscle cancer	1.66e-05	0.00014	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—CNR1—muscle cancer	1.66e-05	0.00014	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—KIT—muscle cancer	1.66e-05	0.00014	CbGpPWpGaD
Vandetanib—ABL1—Axon guidance—VEGFA—muscle cancer	1.66e-05	0.000139	CbGpPWpGaD
Vandetanib—FYN—Disease—FOXO4—muscle cancer	1.65e-05	0.000139	CbGpPWpGaD
Vandetanib—SRC—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	1.64e-05	0.000138	CbGpPWpGaD
Vandetanib—FYN—Axon guidance—VEGFA—muscle cancer	1.64e-05	0.000138	CbGpPWpGaD
Vandetanib—ALB—Metabolism—FH—muscle cancer	1.64e-05	0.000138	CbGpPWpGaD
Vandetanib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.63e-05	0.000137	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IGF2—muscle cancer	1.63e-05	0.000137	CbGpPWpGaD
Vandetanib—FMO1—Metabolism—PTGS2—muscle cancer	1.63e-05	0.000137	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—FOXO4—muscle cancer	1.63e-05	0.000137	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—MDM2—muscle cancer	1.62e-05	0.000136	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—FOXO1—muscle cancer	1.6e-05	0.000135	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CNR1—muscle cancer	1.6e-05	0.000135	CbGpPWpGaD
Vandetanib—YES1—Developmental Biology—VEGFA—muscle cancer	1.59e-05	0.000134	CbGpPWpGaD
Vandetanib—EGFR—Disease—HMGA1—muscle cancer	1.59e-05	0.000134	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—FOXO4—muscle cancer	1.57e-05	0.000132	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—VEGFA—muscle cancer	1.56e-05	0.000132	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—KIT—muscle cancer	1.56e-05	0.000131	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—ENO2—muscle cancer	1.55e-05	0.000131	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CNR1—muscle cancer	1.55e-05	0.00013	CbGpPWpGaD
Vandetanib—EGFR—Immune System—FOXO4—muscle cancer	1.54e-05	0.00013	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—MDM2—muscle cancer	1.54e-05	0.00013	CbGpPWpGaD
Vandetanib—LCK—Disease—HMGA1—muscle cancer	1.53e-05	0.000129	CbGpPWpGaD
Vandetanib—ABCC1—Disease—FOXO4—muscle cancer	1.51e-05	0.000127	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—FOXO1—muscle cancer	1.5e-05	0.000126	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—MED12—muscle cancer	1.5e-05	0.000126	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IGF2—muscle cancer	1.49e-05	0.000126	CbGpPWpGaD
Vandetanib—SRC—Disease—ENO2—muscle cancer	1.49e-05	0.000126	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—KIT—muscle cancer	1.49e-05	0.000126	CbGpPWpGaD
Vandetanib—LCK—Immune System—FOXO4—muscle cancer	1.49e-05	0.000125	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—VEGFA—muscle cancer	1.47e-05	0.000124	CbGpPWpGaD
Vandetanib—FGR—Hemostasis—TP53—muscle cancer	1.46e-05	0.000123	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IGF2—muscle cancer	1.46e-05	0.000122	CbGpPWpGaD
Vandetanib—ERBB3—Disease—KIT—muscle cancer	1.44e-05	0.000121	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IGF2—muscle cancer	1.44e-05	0.000121	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—KIT—muscle cancer	1.44e-05	0.000121	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—KIT—muscle cancer	1.43e-05	0.000121	CbGpPWpGaD
Vandetanib—EGFR—Disease—FOXO4—muscle cancer	1.43e-05	0.00012	CbGpPWpGaD
Vandetanib—EGFR—Axon guidance—VEGFA—muscle cancer	1.42e-05	0.000119	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—MDM2—muscle cancer	1.41e-05	0.000119	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—MDM2—muscle cancer	1.39e-05	0.000117	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PTCH1—muscle cancer	1.39e-05	0.000117	CbGpPWpGaD
Vandetanib—SRC—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.39e-05	0.000117	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—MDM2—muscle cancer	1.38e-05	0.000116	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—KIT—muscle cancer	1.38e-05	0.000116	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—MDM2—muscle cancer	1.38e-05	0.000116	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—FOXO1—muscle cancer	1.37e-05	0.000116	CbGpPWpGaD
Vandetanib—LCK—Disease—FOXO4—muscle cancer	1.37e-05	0.000116	CbGpPWpGaD
Vandetanib—YES1—Immune System—KIT—muscle cancer	1.37e-05	0.000115	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—FOXO1—muscle cancer	1.37e-05	0.000115	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—ENO2—muscle cancer	1.37e-05	0.000115	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PTCH1—muscle cancer	1.37e-05	0.000115	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—IGF2—muscle cancer	1.36e-05	0.000115	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—MDM2—muscle cancer	1.36e-05	0.000114	CbGpPWpGaD
Vandetanib—SRC—Disease—HMGA1—muscle cancer	1.36e-05	0.000114	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—MDM2—muscle cancer	1.36e-05	0.000114	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—VEGFA—muscle cancer	1.34e-05	0.000113	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PTCH1—muscle cancer	1.34e-05	0.000113	CbGpPWpGaD
Vandetanib—BLK—Immune System—MDM2—muscle cancer	1.34e-05	0.000113	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—MDM2—muscle cancer	1.34e-05	0.000113	CbGpPWpGaD
Vandetanib—LYN—Immune System—FOXO1—muscle cancer	1.34e-05	0.000113	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—FOXO1—muscle cancer	1.34e-05	0.000113	CbGpPWpGaD
Vandetanib—FGR—Immune System—MDM2—muscle cancer	1.34e-05	0.000112	CbGpPWpGaD
Vandetanib—ABL1—Immune System—FOXO1—muscle cancer	1.33e-05	0.000112	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—MDM2—muscle cancer	1.33e-05	0.000112	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—FOXO1—muscle cancer	1.32e-05	0.000111	CbGpPWpGaD
Vandetanib—FYN—Immune System—FOXO1—muscle cancer	1.32e-05	0.000111	CbGpPWpGaD
Vandetanib—SRC—Immune System—FOXO4—muscle cancer	1.32e-05	0.000111	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IGF2—muscle cancer	1.31e-05	0.00011	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—MDM2—muscle cancer	1.31e-05	0.00011	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—KIT—muscle cancer	1.27e-05	0.000107	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—FOXO1—muscle cancer	1.26e-05	0.000106	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IGF2—muscle cancer	1.26e-05	0.000106	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—MDM2—muscle cancer	1.23e-05	0.000103	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—VEGFA—muscle cancer	1.23e-05	0.000103	CbGpPWpGaD
Vandetanib—VEGFA—Hemostasis—TP53—muscle cancer	1.22e-05	0.000103	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—KIT—muscle cancer	1.22e-05	0.000103	CbGpPWpGaD
Vandetanib—FYN—Disease—FOXO1—muscle cancer	1.22e-05	0.000103	CbGpPWpGaD
Vandetanib—SRC—Disease—FOXO4—muscle cancer	1.22e-05	0.000102	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.22e-05	0.000102	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—VEGFA—muscle cancer	1.21e-05	0.000102	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—FOXO1—muscle cancer	1.2e-05	0.000101	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—FOXO4—muscle cancer	1.2e-05	0.000101	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—VEGFA—muscle cancer	1.19e-05	0.0001	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—VEGFA—muscle cancer	1.18e-05	9.95e-05	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—TP53—muscle cancer	1.18e-05	9.94e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CNR1—muscle cancer	1.18e-05	9.9e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—MDM2—muscle cancer	1.18e-05	9.89e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—FOXO4—muscle cancer	1.17e-05	9.88e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—VEGFA—muscle cancer	1.17e-05	9.84e-05	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—PTGS2—muscle cancer	1.17e-05	9.81e-05	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—VEGFA—muscle cancer	1.17e-05	9.81e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—FOXO1—muscle cancer	1.16e-05	9.78e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PTCH1—muscle cancer	1.16e-05	9.77e-05	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—VEGFA—muscle cancer	1.16e-05	9.76e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—FOXO4—muscle cancer	1.16e-05	9.72e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CNR1—muscle cancer	1.15e-05	9.7e-05	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—VEGFA—muscle cancer	1.15e-05	9.65e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—KIT—muscle cancer	1.14e-05	9.63e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—FOXO1—muscle cancer	1.14e-05	9.6e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—MDM2—muscle cancer	1.14e-05	9.55e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CNR1—muscle cancer	1.13e-05	9.55e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—MDM2—muscle cancer	1.13e-05	9.53e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—MDM2—muscle cancer	1.13e-05	9.49e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PTCH1—muscle cancer	1.12e-05	9.42e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—FOXO1—muscle cancer	1.12e-05	9.4e-05	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—TP53—muscle cancer	1.11e-05	9.34e-05	CbGpPWpGaD
Vandetanib—ALB—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	1.11e-05	9.32e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—FOXO1—muscle cancer	1.1e-05	9.25e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—PTGS2—muscle cancer	1.09e-05	9.21e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—MDM2—muscle cancer	1.09e-05	9.15e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—MDM2—muscle cancer	1.08e-05	9.08e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—FOXO1—muscle cancer	1.05e-05	8.86e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—KIT—muscle cancer	1.05e-05	8.81e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—KIT—muscle cancer	1.04e-05	8.78e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—KIT—muscle cancer	1.02e-05	8.6e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—KIT—muscle cancer	1.02e-05	8.59e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—VEGFA—muscle cancer	1.02e-05	8.57e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—KIT—muscle cancer	1.02e-05	8.56e-05	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—TP53—muscle cancer	1.02e-05	8.55e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—FOXO1—muscle cancer	1.01e-05	8.54e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—VEGFA—muscle cancer	1.01e-05	8.5e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—KIT—muscle cancer	1.01e-05	8.49e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—KIT—muscle cancer	1.01e-05	8.46e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—MDM2—muscle cancer	1e-05	8.44e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—FOXO4—muscle cancer	9.98e-06	8.4e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PTCH1—muscle cancer	9.91e-06	8.33e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CNR1—muscle cancer	9.8e-06	8.25e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—FOXO1—muscle cancer	9.73e-06	8.19e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—KIT—muscle cancer	9.63e-06	8.11e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—MDM2—muscle cancer	9.63e-06	8.1e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—FOXO4—muscle cancer	9.62e-06	8.1e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IGF2—muscle cancer	9.62e-06	8.1e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—VEGFA—muscle cancer	9.55e-06	8.04e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CNR1—muscle cancer	9.44e-06	7.95e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IGF2—muscle cancer	9.42e-06	7.93e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—TP53—muscle cancer	9.29e-06	7.82e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—KIT—muscle cancer	9.29e-06	7.81e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IGF2—muscle cancer	9.27e-06	7.8e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—MED12—muscle cancer	9.26e-06	7.79e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—KIT—muscle cancer	9.17e-06	7.72e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—MDM2—muscle cancer	9.02e-06	7.59e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—FOXO1—muscle cancer	8.98e-06	7.56e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—KIT—muscle cancer	8.86e-06	7.45e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—FOXO1—muscle cancer	8.85e-06	7.45e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—FH—muscle cancer	8.84e-06	7.44e-05	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—TP53—muscle cancer	8.8e-06	7.41e-05	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—TP53—muscle cancer	8.76e-06	7.37e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—KIT—muscle cancer	8.69e-06	7.31e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—FOXO1—muscle cancer	8.67e-06	7.29e-05	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—TP53—muscle cancer	8.67e-06	7.29e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—VEGFA—muscle cancer	8.62e-06	7.25e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—FOXO1—muscle cancer	8.54e-06	7.18e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FOXO4—muscle cancer	8.52e-06	7.17e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KIT—muscle cancer	8.51e-06	7.16e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—VEGFA—muscle cancer	8.46e-06	7.12e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—ENO2—muscle cancer	8.44e-06	7.1e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—KIT—muscle cancer	8.37e-06	7.05e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CNR1—muscle cancer	8.36e-06	7.04e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—MDM2—muscle cancer	8.25e-06	6.94e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—MDM2—muscle cancer	8.22e-06	6.92e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—MDM2—muscle cancer	8.05e-06	6.77e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—MDM2—muscle cancer	8.04e-06	6.76e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—KIT—muscle cancer	8.02e-06	6.75e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IGF2—muscle cancer	8.01e-06	6.74e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—MDM2—muscle cancer	8.01e-06	6.74e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—MDM2—muscle cancer	7.95e-06	6.69e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—MDM2—muscle cancer	7.92e-06	6.67e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—KIT—muscle cancer	7.73e-06	6.51e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IGF2—muscle cancer	7.72e-06	6.5e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—TP53—muscle cancer	7.7e-06	6.48e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—MDM2—muscle cancer	7.59e-06	6.38e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—KIT—muscle cancer	7.41e-06	6.24e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—FOXO1—muscle cancer	7.37e-06	6.2e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—PTGS2—muscle cancer	7.32e-06	6.16e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—MDM2—muscle cancer	7.31e-06	6.15e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MDM2—muscle cancer	7.22e-06	6.08e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—TP53—muscle cancer	7.22e-06	6.07e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—FOXO1—muscle cancer	7.11e-06	5.98e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—PTGS2—muscle cancer	7.05e-06	5.93e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MDM2—muscle cancer	6.98e-06	5.87e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—VEGFA—muscle cancer	6.85e-06	5.76e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—KIT—muscle cancer	6.85e-06	5.76e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—MDM2—muscle cancer	6.84e-06	5.76e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IGF2—muscle cancer	6.84e-06	5.75e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KIT—muscle cancer	6.75e-06	5.68e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MDM2—muscle cancer	6.7e-06	5.64e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KIT—muscle cancer	6.61e-06	5.56e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.6e-06	5.55e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—MDM2—muscle cancer	6.6e-06	5.55e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KIT—muscle cancer	6.5e-06	5.47e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PTGS2—muscle cancer	6.46e-06	5.44e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—TP53—muscle cancer	6.39e-06	5.38e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—MDM2—muscle cancer	6.32e-06	5.32e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FOXO1—muscle cancer	6.29e-06	5.29e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—VEGFA—muscle cancer	6.26e-06	5.27e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—VEGFA—muscle cancer	6.1e-06	5.13e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—PTGS2—muscle cancer	6.09e-06	5.13e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—MDM2—muscle cancer	6.09e-06	5.12e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—VEGFA—muscle cancer	6.04e-06	5.08e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—PTGS2—muscle cancer	5.87e-06	4.94e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—MDM2—muscle cancer	5.84e-06	4.91e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—VEGFA—muscle cancer	5.71e-06	4.8e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KIT—muscle cancer	5.62e-06	4.73e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KIT—muscle cancer	5.41e-06	4.56e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTGS2—muscle cancer	5.41e-06	4.55e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—MDM2—muscle cancer	5.39e-06	4.54e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MDM2—muscle cancer	5.31e-06	4.47e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—VEGFA—muscle cancer	5.3e-06	4.46e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MDM2—muscle cancer	5.2e-06	4.38e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PTGS2—muscle cancer	5.2e-06	4.37e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—muscle cancer	5.17e-06	4.35e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MDM2—muscle cancer	5.12e-06	4.31e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MED12—muscle cancer	5e-06	4.2e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KIT—muscle cancer	4.79e-06	4.03e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—muscle cancer	4.76e-06	4.01e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—muscle cancer	4.73e-06	3.98e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—muscle cancer	4.61e-06	3.88e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—muscle cancer	4.56e-06	3.84e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ENO2—muscle cancer	4.55e-06	3.83e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MDM2—muscle cancer	4.42e-06	3.72e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—muscle cancer	4.31e-06	3.63e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MDM2—muscle cancer	4.26e-06	3.59e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—muscle cancer	4.14e-06	3.49e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—muscle cancer	4.04e-06	3.4e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—muscle cancer	4e-06	3.37e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—muscle cancer	3.95e-06	3.32e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—muscle cancer	3.89e-06	3.27e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MDM2—muscle cancer	3.78e-06	3.18e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—muscle cancer	3.36e-06	2.83e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—muscle cancer	3.24e-06	2.72e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—muscle cancer	3.05e-06	2.57e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—muscle cancer	2.99e-06	2.51e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—muscle cancer	2.94e-06	2.47e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—muscle cancer	2.94e-06	2.47e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—muscle cancer	2.87e-06	2.41e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—muscle cancer	2.54e-06	2.14e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—muscle cancer	2.45e-06	2.06e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—muscle cancer	2.17e-06	1.82e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—muscle cancer	1.59e-06	1.33e-05	CbGpPWpGaD
